ID   LNCaP C4-2B MDVR
AC   CVCL_F0L5
SY   C4-2B MDVR; LNCaP C4-2B MR; C4-2B MR
RX   PubMed=24740322;
RX   PubMed=28500234;
CC   Population: Caucasian.
CC   Characteristics: Resistant to 20 mmol/L of enzalutamide (PubMed=24740322).
CC   Selected for resistance to: ChEBI; CHEBI_68534; Enzalutamide (Xtandi; MDV-3100).
CC   Sequence variation: Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4784 ! LNCaP C4-2B
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=24740322; DOI=10.1158/1078-0432.CCR-13-3296; PMCID=PMC4058390;
RA   Liu, Cheng-Fei
RA   Lou, Wei
RA   Zhu, Ye-Zi
RA   Nadiminty, Nagalakshmi
RA   Schwartz, Chad T.
RA   Evans, Christopher P.
RA   Gao, Allen C.
RT   "Niclosamide inhibits androgen receptor variants expression and
RT   overcomes enzalutamide resistance in castration-resistant prostate
RT   cancer.";
RL   Clin. Cancer Res. 20:3198-3210(2014).
//
RX   PubMed=28500234; DOI=10.1158/1535-7163.MCT-16-0912; PMCID=PMC5544572;
RA   Liu, Cheng-Fei
RA   Armstrong, Cameron M.
RA   Lou, Wei
RA   Lombard, Alan P.
RA   Cucchiara, Vito
RA   Gu, Xin-Wei
RA   Yang, Joy C.
RA   Nadiminty, Nagalakshmi
RA   Pan, Chong-Xian
RA   Evans, Christopher P.
RA   Gao, Allen C.
RT   "Niclosamide and bicalutamide combination treatment overcomes
RT   enzalutamide- and bicalutamide-resistant prostate cancer.";
RL   Mol. Cancer Ther. 16:1521-1530(2017).
//